Humana(HUM) - 2025 Q1 - Quarterly Report

Financial Performance - Humana's net income for Q1 2025 was $1.2 billion, or$ 10.30 per diluted share, compared to $0.7 billion, or$ 6.11 per diluted share in Q1 2024, reflecting a 68.1% increase [127]. - Total revenues increased by 8.4% to $32.1 billion in Q1 2025, up from$ 29.6 billion in Q1 2024, driven by an 8.0% rise in insurance premiums [133]. - The benefit ratio improved to 87.0% in Q1 2025 from 88.9% in Q1 2024, indicating better underwriting profitability [133]. - Operating costs rose by 11.1% to $3.4 billion in Q1 2025, compared to$ 3.0 billion in Q1 2024, reflecting increased administrative spending [133]. - Consolidated premiums revenue increased by $2.3 billion, or 8.0%, from$ 28.3 billion in the 2024 quarter to $30.5 billion in the 2025 quarter, driven by higher per member Medicare premiums and membership growth in stand-alone PDP and state-based contracts [135]. - Consolidated services revenue rose by$ 272 million, or 25.6%, from $1.1 billion in the 2024 quarter to$ 1.3 billion in the 2025 quarter, primarily due to growth in the primary care business [136]. - Consolidated benefits expense increased by $1.4 billion, or 5.6%, from$ 25.1 billion in the 2024 quarter to $26.5 billion in the 2025 quarter, with the consolidated benefit ratio decreasing by 190 basis points to 87.0% [138]. Membership and Segments - Approximately 3.5 million, or 67%, of individual Medicare Advantage members were in value-based relationships as of March 31, 2025, down from 69% a year earlier [126]. - Individual Medicare Advantage membership decreased by 333,100 members, or 6.0%, from March 31, 2024, to March 31, 2025, including a net decrease of 123,100 D-SNP members [149]. - Group Medicare Advantage membership increased by 21,100 members, or 3.8%, from March 31, 2024, to March 31, 2025 [150]. - State-based contracts and other membership increased by 346,700 members, or 27.5%, reflecting new contracts implemented in Oklahoma and Indiana [151]. - The CenterWell segment's revenue grew by 37.5% to$ 1.1 billion in Q1 2025, up from $0.8 billion in Q1 2024, highlighting strong performance in healthcare services [133]. - CenterWell segment income from operations increased by$ 0.1 billion, or 39.0%, from $0.3 billion in the 2024 quarter to$ 0.4 billion in the 2025 quarter [158]. - CenterWell services revenue increased by $0.3 billion, or 37.5%, from$ 0.8 billion in the 2024 quarter to $1.1 billion in the 2025 quarter, primarily due to growth in the primary care business [159]. Tax and Investment - The effective tax rate decreased slightly to 24.6% in Q1 2025 from 25.3% in Q1 2024, reflecting changes in tax liabilities [133]. - Investment income decreased by 8.3% to$ 264 million in Q1 2025, down from $288 million in Q1 2024, indicating challenges in investment performance [133]. - Investment income decreased by$ 24 million, or 8.3%, from $288 million in the 2024 quarter to$ 264 million in the 2025 quarter, mainly due to lower interest income on debt securities [137]. - The average duration of the investment portfolio was approximately 3.4 years as of March 31, 2025, indicating sensitivity to interest rate changes [191]. - The company experienced a net unrealized loss position of $1.1 billion on its investment portfolio as of March 31, 2025, down from a loss of$ 1.4 billion at December 31, 2024 [190]. Cash Flow and Capital Management - Cash and cash equivalents increased to approximately $4.3 billion at March 31, 2025, up from$ 2.2 billion at December 31, 2024 [163]. - Net cash provided by operating activities decreased to $331 million in the 2025 quarter from$ 423 million in the 2024 quarter, primarily due to unfavorable working capital impacts [164]. - Total net receivables rose to $4.459 billion at March 31, 2025, compared to$ 2.704 billion at December 31, 2024, reflecting higher Medicare premiums and membership growth [166]. - Total net capital expenditures, excluding acquisitions, were $95 million in the 2025 quarter, down from$ 177 million in the 2024 quarter [168]. - The company issued $750 million of 5.550% unsecured senior notes due May 1, 2035, and net proceeds from these offerings were$ 1.481 billion [171]. - The company repurchased common shares for $702 million in the 2024 quarter and paid dividends of$ 108 million in the 2025 quarter [176][177]. - Aggregate statutory capital and surplus of state-regulated subsidiaries was approximately $13.2 billion, exceeding minimum regulatory requirements of$ 11.4 billion [187]. - Future liquidity sources are expected to be adequate for ongoing operations, acquisitions, and capital expenditures for at least the next twelve months [182]. Strategic Focus - Humana's strategy focuses on integrated care delivery, aiming for long-term growth in membership and earnings through enhanced member engagement and data analytics [126]. - Charges related to value creation initiatives amounted to $24 million in Q1 2025, compared to$ 29 million in Q1 2024, primarily due to asset impairments and workforce optimization [119].